A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours

A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours

Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: European Journal of Cancer - Volume 51, Issue 16, November 2015, Pages 2275-2284

A. Suder, J.E. Ang, F. Kyle, D. Harris, S. Rudman, R. Kristeleit, F. Solca, M. Uttenreuther-Fischer, K. Pemberton, K. Pelling, D. Schnell, J. de Bono, J. Spicer,